HUTCHMED Showcases at 2024 ASCO Annual Meeting

HUTCHMED (China) Limited ("HUTCHMED") has announced the presentation of new and updated data from multiple studies of its proprietary compounds at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 31 to June 4, 2024, in Chicago and online.

One of the key studies to be presented is a Phase II trial of fruquintinib combined with sintilimab in 98 patients with endometrial cancer (EMC) possessing proficient mismatch repair (pMMR) status. This study supports a New Drug Application (NDA) in China. The trial's primary endpoint was the objective response rate (ORR) as per RECIST v1.1 criteria, evaluated by an independent committee. Results showed significant efficacy improvements in advanced EMC patients with a manageable safety profile, regardless of previous bevacizumab treatment. The median follow-up was 15.7 months, with an ORR of 35.6% among 87 evaluable patients, including two complete responses. The disease control rate (DCR) was 88.5%, with 80.7% of patients remaining in response at nine months. The median progression-free survival (PFS) was 9.5 months, while the median overall survival (OS) was 21.3 months.

Additionally, updated efficacy data from the FRUTIGA Phase III study of fruquintinib in second-line gastric cancer will be presented, along with new insights into the FRESCO and FRESCO-2 Phase III studies in colorectal cancer, combining surufatinib in small cell lung cancer, and initial clinical data for the ERK1/2 inhibitor HMPL-295.

The presentations will cover a broad spectrum of studies, including:

- Fruquintinib plus Sintilimab in advanced EMC patients with pMMR status, presented by Xiaohua Wu from Fudan University Shanghai Cancer Center.
- Efficacy and safety of fruquintinib in metastatic colorectal cancer from the FRESCO and FRESCO-2 studies, presented by Tanios S. Bekaii-Saab of Mayo Clinic.
- Fruquintinib as a second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma in the FRUTIGA study, presented by Feng Wang of Sun Yat-Sen University Cancer Center.
- Surufatinib plus PD-1/L1 inhibitors as maintenance therapy in extensive-stage small cell lung cancer, presented by Yi Hu from Chinese PLA General Hospital.
- First-in-human study of the ERK1/2 inhibitor HMPL-295 in advanced solid tumors, presented by Xianjun Yu from Fudan University Shanghai Cancer Center.

Further insights will be shared on various investigator-initiated studies, including:

- Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer.
- Propensity score-matched comparison of fruquintinib versus fruquintinib combined with PD-1 inhibitors for microsatellite stability metastatic colorectal cancer.
- Phase Ib/II trial of hepatic arterial infusion chemotherapy combined with fruquintinib for third-line therapy in refractory colorectal cancer.

Additional presentations will include studies on the efficacy and safety of fruquintinib combined with other treatments for various types of cancer, including bone and soft tissue sarcomas, esophageal squamous cell cancer, and radioiodine-refractory differentiated thyroid cancer.

HUTCHMED is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. With around 5,000 employees, including about 1,800 in oncology/immunology, the company aims to bring innovative cancer treatments to patients globally. The company's recent data presentations at the ASCO Annual Meeting highlight its commitment to advancing cancer treatment through rigorous clinical research and development.